JBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Jade Biosciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$13.83+0.36 (+2.67%)
Close on Oct 19, 2026
- Market cap
- $844.33M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$4.46 (+47.60%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $844.33M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.92
- Dividend yield
- –
- Free cash flow yield
- -11.24%
Fundamentals
- Net income
- -$153.24M
- EPS, diluted
- -$3.19
- Free cash flow
- -$94.89M
- Book value per share
- $7.21
- Diluted shares
- 61M
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Operating income
-$164.74M
Net income
-$153.24M
EPS, diluted
–
Free cash flow
–
Reported periodTrailing twelve months